5.94
-0.27(-4.35%)
Currency In USD
| Previous Close | 6.21 |
| Open | 6.23 |
| Day High | 6.23 |
| Day Low | 5.88 |
| 52-Week High | 13.68 |
| 52-Week Low | 4.25 |
| Volume | 734,065 |
| Average Volume | 777,139 |
| Market Cap | 326.1M |
| PE | -10.61 |
| EPS | -0.56 |
| Moving Average 50 Days | 5.31 |
| Moving Average 200 Days | 5.45 |
| Change | -0.27 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $848.57 as of January 16, 2026 at a share price of $5.94. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 3 years ago, it would be worth $2,700 as of January 16, 2026 at a share price of $5.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
GlobeNewswire Inc.
Nov 17, 2025 9:05 PM GMT
NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
GlobeNewswire Inc.
Nov 04, 2025 2:00 PM GMT
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3 clinical trial of CAN-2409 in newly diagnosed, loc
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 03, 2025 1:05 PM GMT
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer